Clinical assessment of the condition of women of reproductive age with adenomyosis after experiencing COVID-19

Abstract

Annotation. The relevance of the gynecological disease adenomyosis (N80.0) is beyond doubt, as this pathology is a serious problem today both in medicine and in society. The aim is to study the clinical condition of women of reproductive age with adenomyosis after suffering COVID-19. 150 women of reproductive age were examined after suffering COVID-19 disease, 120 of them with adenomyosis. The results obtained were processed using the methods of mathematical statistics and using the MS Excel XP, Statistica 6.0 software package using Student's parametric test. At the same time, differences were considered statistically significant at p<0.05. A clinical assessment of the condition of women of reproductive age with adenomyosis after suffering COVID-19 confirmed a significantly more severe course of adenomyosis in the early post-COVID period. After undergoing COVID-19, the frequency of complaints of general malaise, headaches, lethargy, pain in the joints, muscles, and pelvis in women aggravated by adenomyosis significantly increased. The more severe the degree of the disease (I-II, III-IV), the worse was the general condition of the examined patients. The frequency of complaints about general malaise, exacerbation of extragenital diseases (cardiovascular system, gastrointestinal tract, hepatobiliary system, anemia, etc.), gynecological pathology, including disorders of menstrual function, volume of menstrual blood loss, pelvic pain syndrome, presence of processes of inflammatory (infectious) etiology increased significantly. Determining the clinical assessment of the condition of women of reproductive age with adenomyosis after suffering COVID-19 is of fundamental practical importance for determining the tactics of managing this cohort of patients with the aim of timely qualified prevention of possible complications. Prospects for further research are aimed at developing and implementing an algorithm for managing women of reproductive age with adenomyosis after suffering COVID-19.